What smart money is saying about Perrigo
3 funds in our archive have pitched Perrigo, most recently O’Keefe Stevens Advisory in September 2026.
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2024 and Q3 2026, 2 fund letters reported a position in Perrigo, with 1 buy (opened or added).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 2 | 1 | 0 | 1 |
| Q2 2025 | 0 | 0 | 0 | 1 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions · 1 move
- September 2026
“Information Technology, Consumer Discretionary, and Financials holdings also hindered results. Conversely, selection within Health Care, a space that has been battered over the last several years outside of speculative areas like biotechnology, contributed most, with Charles River Laboratories, Integer Holdings, and Perrigo signicantly outperforming benchmark constituents.”
Perrigo - September 2026
“With the 10-year above 5% and small caps down 7.2%, the natural question is how our more levered holdings are holding up. Our three most levered positions (PRGO, BAX, SHC) in the portfolio all happen to be in the Healthcare space. Perrigo (PRGO) +42.1%. Our biggest loser in 2025 and our Q1 laggard was our best performer in Q3. While the business is far from fixed, when things go from bad to less bad, the stock usually reacts. The business is not fixed: Q2 core sales fell 3%, and core adjusted EPS fell 21%. Perrigo sold Dermacosmetics for ~$359m, paid down $759m of debt in the first half, and extended its credit agreement to 2031. Net debt is ~$2.9B, with a target at or slightly below 4.0x. The infant formula review is ongoing with no outcome, and an interim CEO is in place. Given the ongoing turmoil at the management level, it's unsurprising that buyout rumors are swirling. A sale of the company is possible but speculative, and there is no assurance that any transaction will occur. Additionally, this dividend aristocrat does not necessarily have the healthiest balance sheet to keep this raise going. Therefore, the easy way out is to sell, avoiding this potentially negative reaction to the stock. We continue to hold Perrigo, most recently adding to the position in February 2026.”
Perrigo
Fund coverage · 3 theses
- O’Keefe Stevens AdvisorySeptember 2026
Perrigo is a beaten-down, uncorrelated consumer healthcare name where deleveraging, a possible buyout catalyst, and factor reversal could drive a sharp rebound.
Read the full thesis - Aristotle Small Mid Cap EquityJune 2025
Perrigo is a consumer health company undergoing a turnaround with new management's self-help initiatives aimed at improving profitability and driving above-average earnings growth.
Read the full thesis - White Falcon Capital ManagementDecember 2024
Perrigo is poised for significant growth with the launch of Opill, the first FDA-approved over-the-counter contraception, expected to contribute positively to earnings by 2025-26, potentially doubling its share price to $50.
Read the full thesis
Read every full thesis on Perrigo
Read all 3 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→